Philip Morris
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 283 | Existing positions closed: 106
23% more funds holding in top 10
Funds holding in top 10: 65 [Q3] → 80 (+15) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 982 | Existing positions reduced: 819
6% more funds holding
Funds holding: 2,315 [Q3] → 2,444 (+129) [Q4]
1% less capital invested
Capital invested by funds: $153B [Q3] → $152B (-$1.47B) [Q4]
0.96% less ownership
Funds ownership: 81.3% [Q3] → 80.33% (-0.96%) [Q4]
1% less call options, than puts
Call options by funds: $993M | Put options by funds: $1.01B
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$120
23%
downside
Avg. target
$151
3%
downside
High target
$175
13%
upside
5 analyst ratings
4 positive
80%
0 neutral
0%
1 negative
20%
Barclays Gaurav Jain 44% 1-year accuracy 4 / 9 met price target | 13%upside $175 | Overweight Maintained | 26 Feb 2025 |
JP Morgan Jared Dinges 100% 1-year accuracy 3 / 3 met price target | 3%upside $160 | Overweight Maintained | 18 Feb 2025 |
Stifel Matthew Smith 52% 1-year accuracy 13 / 25 met price target | 3%upside $160 | Buy Maintained | 7 Feb 2025 |
UBS Faham Baig 17% 1-year accuracy 1 / 6 met price target | 23%downside $120 | Sell Maintained | 7 Feb 2025 |
Morgan Stanley Eric Serotta 100% 1-year accuracy 2 / 2 met price target | 10%downside $140 | Overweight Initiated | 16 Jan 2025 |
Financial journalist opinion
Based on 29 articles about PM published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Resilient Sin Stocks to Power Up Your Investment Portfolio
Sin stocks are poised to thrive in any market, offering stability, strong cash flow and high returns. Discover three top picks poised to boost your portfolio gains.
Positive
Seeking Alpha
2 days ago
Philip Morris: Outpacing The Market, With More Room To Run
Philip Morris International remains a strong buy due to its dominance in smoke-free products like IQOS and ZYN, outperforming the S&P 500 by over 20% since my last article. The latest earnings report showed robust growth, with total revenue up 10% and smoke-free product sales up 15%, highlighting PM's market leadership of the hottest growth story in consumer staples. Currency fluctuations have always posed a risk, but a weakening dollar could boost PM's earnings further, aligning with a favorable macroeconomic backdrop for tobacco stocks with international end markets.
Positive
Reuters
3 days ago
Philip Morris' heated tobacco device IQOS goes on sale in Texas
Philip Morris International officially launched IQOS in Austin, Texas, on Thursday, kicking off efforts by the world's largest cigarette maker to build a market for its flagship heated tobacco device in the United States.
Positive
Seeking Alpha
6 days ago
The Most 'Unethical' Dividend Portfolio Ever: Paying Your Bills With The Vices Of Humankind
Human vices like alcohol, tobacco, and sex persist; companies in these industries remain profitable and offer attractive dividends despite societal disapproval. The tobacco industry is in slow decline but still profitable; British American Tobacco, Altria, and Philip Morris offer high dividends and are transitioning to less harmful products. Alcohol consumption remains high despite narratives of decline; Brown-Forman and Constellation Brands are undervalued with strong fundamentals and dividends.
Positive
Investors Business Daily
6 days ago
This Tobacco Giant's Business Shift Moves It Near The Top Of The S&P 500
Philip Morris is soaring on the Zyn nicotine pouch craze and is now in a valid base, trading just below a buy point. The post This Tobacco Giant's Business Shift Moves It Near The Top Of The S&P 500 appeared first on Investor's Business Daily.
Neutral
Zacks Investment Research
6 days ago
The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research
Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research are included in this Analyst Blog.
Positive
The Motley Fool
6 days ago
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks
Data is abundant, if not overwhelming, on Wall Street. Between earnings season -- the six-week period when a majority of S&P 500 companies unveil their quarterly operating results -- and near-daily economic data releases, it can be easy to miss something important.
Positive
Seeking Alpha
1 week ago
Philip Morris International Is On Fire With Zyn: More Gains Ahead?
Philip Morris International has surged 66% in the past year, outperforming even Nvidia amidst a market shift towards quality investments. Zyn, the company's nicotine pouch product, is flying off the shelves. Zyn's popularity among fraternities and affluent younger consumers has led to massive supply shortages.
Positive
The Motley Fool
1 week ago
Best Stock to Buy Right Now: Altria vs. Philip Morris International
Tobacco stock investors don't have a lot of choices these days, so if you're looking to invest in one of these classic dividend payers, two of the first stocks that are likely to come up on your radar are Altria (MO -1.15%) and Philip Morris International (PM -0.74%).
Neutral
ETF Trends
1 week ago
My Favorite Stocks to Add Right Now
A friend of mine keeps posting every day about how much money she has lost in the stock market. I finally had to comment on her post: “Stop checking your account.
Charts implemented using Lightweight Charts™